Consensus Alvotech Nasdaq Stockholm

Stocks

ALVO SDB

SE0025011463

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 03:00:00 24/10/26 am AEDT			5-day change	1st Jan Change
46.05 ^SEK	-6.40%		-11.78%	-0.84%

21/10	Nordic stocks in North America - Ericsson up 0.7 percent	FW
21/10	Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says	MT

8c.oVr1e0SgtqjXZVTcoOHIZAjdKMtMKCkF_4cCJsobNNQ.zm6ZSA3Oz52HFQKaxZesCUKqG48BUkt3ithnC_hwApvIDqMoLZXf-7MpBQ~69e940712cd1f399e3d6c29caf7cb26d

Analysts' recommendations: Alvotech

21/10	Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says	MT
17/09	Alvotech Shares Rise After Double Upgrade From Barclays	MT
16/09	Barclays Upgrades Alvotech to Overweight From Underweight, Adjusts PT to $8 From $4	MT
25/08	Alvotech's Q4 Approval, Launch Timelines Remain Intact, UBS Says	MT
24/08	BofA Securities Initiates Alvotech at Buy With $7 Price Target	MT
25/03	UBS Adjusts Alvotech Price Target to $6 From $10, Maintains Buy Rating	MT
24/03	Deutsche Bank Adjusts Alvotech Price Target to $4 From $8, Maintains Hold Rating	MT
22/12	Stockholm Bullets - Viscaria Soars on Buy Recommendation	FW
19/11	UBS Adjusts Alvotech Price Target to $10 From $13, Maintains Buy Rating	MT
05/11	Alvotech Shares Fall After Deutsche Bank Downgrade	MT
05/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Adjusts Price Target to $8 From $14	MT
04/11	Deutsche Bank Downgrades Alvotech to Hold From Buy, Cuts Price Target to $8 From $14	MT
04/11	Alvotech Shares Slide on FDA Demands for Application for Arthritis Drug Biosimilar	DJ
04/11	Top Premarket Decliners	MT
03/11	Alvotech's Potential Arthritis Biosimilar Receives FDA Complete Response Letter; Shares Down Pre-Bell	MT
03/11	Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05	CI
15/10/25	Alvotech Shares Rise After Morgan Stanley Upgrade	MT
14/10/25	Morgan Stanley Upgrades Alvotech to Overweight From Equalweight, Price Target is $14	MT
24/09/25	Alvotech Set to Benefit from Opportunities in Biosimilars Market, Deutsche Bank Says	MT
23/09/25	Deutsche Bank Upgrades Alvotech to Buy From Hold, Price Target is $14	MT
21/07/25	UBS Says Alvotech Set for H2 Growth on Pipeline Launches, Private Label Deal	MT
18/07/25	UBS Adjusts Price Target on Alvotech to $14 From $16, Maintains Buy Rating	MT
26/07/24	Barclays Adjusts Price Target on Alvotech to $18 From $22, Maintains Overweight Rating	MT
25/05/24	Barclays Adjusts Price Target on Alvotech to $22 From $20, Maintains Overweight Rating	MT
23/03/24	Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+35.78%
	ARGENX SE					+28.93%
	LONZA GROUP AG					+10.89%
	IQVIA HOLDINGS INC.					+8.75%
	BEONE MEDICINES AG					+14.18%
	REVOLUTION MEDICINES, INC.					+37.21%
	CELLTRION, INC.					+37.85%
	WUXI BIOLOGICS (CAYMAN) INC.					+32.7%
	GENMAB A/S					+4.59%
	Average					+23.43%
	Weighted average by Cap.					+23.82%